Beringea

Beringea's track record of three decades of successful investing across a wide range of sectors has cultivated an exceptional community of rapidly-scaling companies and their founders.

Beringea is a transatlantic venture capital investor that seeks to create lasting success for rapidly scaling entrepreneurial companies. They provide patient and intelligent capital and a global footprint to back entrepreneurs throughout their journey.

Beringea is a transatlantic venture capital seeking to create lasting success for rapidly scaling entrepreneurial companies. Beringea has raised a total of $263.5M across 5 funds, their latest being ProVen VCT Fund. This fund was announced on Apr 16, 2019 and raised a total of £39M.

Beringea has managed the ProVen VCT and ProVen Growth & Income VCT since their launches in 2000 and 2001. The ProVen VCTs together manage more than £300m, and they invest in a diversified portfolio of VCT-qualifying private companies. Investments are identified by Beringea as having, in its opinion, significant growth potential.

Beringea U.S. manages a family of funds which targets $2-10 million preferred equity investment opportunities in quickly scaling companies across a range of sectors.

What they look for:

-Geographic preference: Midwest U.S.

-Key business metrics: Proven business model targeting a large and growing addressable market; scalable financial and operating metrics; commercially viable product, service, or technology with a defensible market position; exceptional management team with clear vision and passion for the company's future.

-Financial: High-growth companies with meaningful commercial traction, typically reflected by ARR in excess of $3 million.

-Stage: Series A, Growth or later.

For the uS, they typically invest between $2-10 million in preferred equity, focusing on Midwest-based companies in fast-growing sectors with meaningful revenue at the Series A (or later) expansion or small buy-out stage. For the UK and Europe, they typically make an initial investment between £1-10 million into companies turning over approximately £1 million or more. We tend to lead Series A or Series B rounds, with further funding available for follow-on investments.

Portfolio: Papier, Genomenon, Moonshot, Floyd.